Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709247PMC
http://dx.doi.org/10.1586/ecp.11.65DOI Listing

Publication Analysis

Top Keywords

clinical pharmacology
4
pharmacology neonates
4
neonates young
4
young infants
4
infants benefit
4
benefit population-tailored
4
population-tailored approach
4
clinical
1
neonates
1
young
1

Similar Publications

Background And Aim: Tonsil-surgery is a common treatment for tonsillitis and upper-airway obstruction. Health benefits are a key point of clinical concern. Aim: To evaluate health benefits 6-months after pediatric tonsil-surgery and to examine the influence of the perioperative period on health-related quality of life (HRQoL).

View Article and Find Full Text PDF

Background: Many studies indicate that high and multiple doses of anabolic-androgenic steroids (AAS) for athletic enhancement can result in serious and irreversible adverse effects. A study that includes laboratory blood testing to evaluate the direct effects of AAS agents among users has not been previously undertaken. The purpose of this study was to investigate the adverse effects of the use of AAS by athletes and to determine whether AAS use leads to changes in certain blood parameters.

View Article and Find Full Text PDF

Background: Diabetic ketoacidosis (DKA) is a serious and acute complication of diabetes mellitus. In Ethiopia, the mortality associated with acute diabetes complications ranges from 9.8% to 12%.

View Article and Find Full Text PDF

Introduction Acute poisoning in children is still a global health concern that necessitates visiting the emergency department that might associated with morbidity and mortality. It has an impact on social, economic, and health issues, particularly for children under five who account for the majority of poisonings worldwide. Poisoning can result in mild cases, serious complications, or even death; oral ingestion is the most common way that poisoning occurs in children.

View Article and Find Full Text PDF

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent liver pathology in need of novel pharmacological treatments to complement lifestyle-based interventions. Nuclear receptor agonists have been under scrutiny as potential pharmacological targets and as of today, resmetirom, a thyroid hormone receptor b agonist, is the only approved agent. The dual PPAR α and δ agonist elafibranor has also undergone extensive clinical testing, which reached the phase III clinical trial but failed to demonstrate a beneficial effect on MASLD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!